Sugammadex
Conditions
Brief summary
This is a single site, prospective, non-blinded, non-randomized, before/after study. This study is designed to evaluate the impact of monitoring and reversal guidelines for neuromuscular blocking drugs on the post-operative outcomes for patients undergoing laparoscopic gastric bypass surgery.
Interventions
DEVICEQuantitative Neuromuscular Function Monitoring
Quantitative electromyographic (EMG) monitoring
Sponsors
University of California, Davis
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* age greater than 18 years * scheduled for an elective laparoscopic gastric bypass procedure
Exclusion criteria
* age less than 18 years * pregnancy * prisoners * significant co-existing lung disease including asthma or chronic obstructive pulmonary disease (COPD) requiring regular medication * patients who require supplemental oxygen pre-operatively to maintain a hemoglobin saturation (SpO2\>98%)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Oxygen desaturation | 24 hours | Incidence and magnitude of significant oxygen desaturation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hospital Length of stay | 7 days | Length of stay (Hours) |
| Success rate for wearable device | 24 hours | Rate of compliance (%) |
| The rate of compliance with muscle relaxant monitoring and reversal protocols | 24 hours | Rate of compliance (%) |
| Post-operative unit length of stay | 7 days | Length of stay (Hours) |
| Total sugammadex dose | 24 hours | Total dose (mg/kg) |
| Post-operative supplemental oxygen requirement | 24 hours | Oxygen requirement (FiO2%/hr) |
| Total intraoperative rocuronium use | 24 hours | Total dose/kg/hr (mg/kg/hr) |
Countries
United States
Contacts
Primary ContactAna P Arias, BS
Backup ContactJulio J Arana Pineda, BA
Outcome results
None listed